Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
The enzyme 2-aminoadipic-6-semialdehyde dehydrogenase () plays a crucial role in metabolic pathways and has emerged as a significant player in multiple pathological conditions, including cancer and cardiomyopathies. has been implicated in colorectal cancer (CRC), particularly in microsatellite instability (MSI)-high tumors, in which genetic alterations may contribute to chemotherapy resistance and tumor progression. In addition to CRC, dysregulation of has been observed in hepatocellular carcinoma (HCC) and lung adenocarcinoma (LUAD), where it influences lipid metabolism and oncogenic pathways. Additionally, emerging evidence suggests a strong link between and cardiomyopathies, highlighting its potential as a biomarker of ischemic cardiomyopathy-induced heart failure. At the molecular level, functions in ATP binding and acid-thiol ligase activity, and plays a pivotal role in stress responses, lysine metabolism, and oxidative stress protection. Its association with metabolic reprogramming and the tumor microenvironment suggests that targeting could enhance current therapeutic strategies for cancer and cardiovascular diseases. This review comprehensively explores the diverse roles of , emphasizing its potential as a prognostic biomarker and therapeutic target for multiple diseases. A deeper understanding of may pave the way for novel treatment strategies that integrate metabolic modulation with conventional therapies and improve clinical outcomes in both oncology and cardiology.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.21873/anticanres.17679 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
MicroRNAs in anthracycline cardiotoxicity: biomarkers, mechanisms, and therapeutic advances.
Front Cardiovasc Med
August 2025
Department of Rehabilitation Medicine, School of Acupuncture-Moxibustion and Tuina and School of Health Preservation and Rehabilitation, Nanjing University of Chinese Medicine, Nanjing, China.
Background: Anthracycline-based chemotherapy is a highly effective treatment for numerous cancers, yet its clinical use is severely limited by cumulative, dose-dependent cardiotoxicity. MicroRNAs (miRNAs), as key post-transcriptional regulators of gene expression, play a pivotal role in the pathophysiology of cardiovascular disease, but their specific functions in anthracycline-induced cardiotoxicity (AIC) require systematic elucidation.
Purpose: This review aims to systematically summarize current research on the key miRNAs, their molecular targets, and associated signaling pathways that regulate AIC, while also exploring their potential as biomarkers for early diagnosis and as therapeutic targets for intervention.
Reduced-dose vs full-dose direct oral anticoagulants for extended treatment of venous thromboembolism: a meta-analysis of randomized controlled trials.
Res Pract Thromb Haemost
July 2025
Division of Cardiology, Ahmanson-UCLA Cardiomyopathy Center, University of California Los Angeles, Los Angeles, California, USA.
Background: Venous thromboembolism (VTE) is a major cause of cardiovascular morbidity and mortality globally. Although direct oral anticoagulants (DOACs) have improved extended VTE treatment, the optimal dose for balancing efficacy and safety remains unclear.
Objectives: This systematic review and meta-analysis aimed to evaluate the efficacy and safety of reduced-dose DOACs vs full-dose regimens during extended anticoagulation for VTE.
The emerging role of Nrf2 in heart failure: From cardioprotection to therapeutic approaches.
ESC Heart Fail
September 2025
Department of Clinical and Molecular Medicine, Sapienza University, Rome, Italy.
Heart failure (HF) is a multifactorial and pathophysiological complex syndrome, involving not only neurohormonal activation but also oxidative stress, chronic low-grade inflammation, and metabolic derangements. Central to the cellular defence against oxidative damage is nuclear factor erythroid 2-related factor 2 (Nrf2), a transcription factor that orchestrates antioxidant and cytoprotective responses. Preclinical in vitro and in vivo studies reveal that Nrf2 signalling is consistently impaired in HF, contributing to the progression of myocardial dysfunction.
View Article and Find Full Text PDFCoronary embolisation of a left ventricular fibroelastoma mimicking a thrombus and triggering Takotsubo cardiomyopathy.
BMJ Case Rep
September 2025
Interventional Cardiology, Emory University School of Medicine, Atlanta, Georgia, USA.
We describe a case of a woman in her 70s who presented with acute chest pain and ST-segment elevation on ECG. Multimodality cardiac imaging confirmed Takotsubo cardiomyopathy alongside a pedunculated left ventricular mass, presumed to be a thrombus, with suspected embolisation to the left anterior descending artery, triggering an acute myocardial infarction. She received guideline-directed medical therapy for heart failure and anticoagulation for the thrombus.
View Article and Find Full Text PDFCardiac resynchronization therapy in cancer patients with chemotherapy-induced cardiomyopathy: a mini review.
Heart Fail Rev
September 2025
Division of Provincial Cardiology, Department of Translational Medicine, University of Ferrara, Ferrara, Italy.
Chemotherapy-induced cardiomyopathy (CHIC) represents a growing clinical challenge due to the increasing use of cardiotoxic treatments. These therapies can lead to progressive myocardial dysfunction, ultimately resulting in heart failure. Cardiac resynchronization therapy (CRT) has been widely investigated in selected patients with chronic heart failure; however, those with CHIC remain underrepresented in CRT trials.
View Article and Find Full Text PDF